Shareholders approve Hatri Pharma amalgamation with Venmax

Scheme filed with the NCLTStrategic Transactions View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.1%Reaction day

₹13.99

prior close

₹15.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.7%-1.6% vs market

Pharmaceuticals peers, median of 173sector+2.0%-1.9% vs sector

On the reaction day the stock moved 1.6 pts less than Nifty Microcap 250 and 1.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.1+1.7-1.6+2.0-1.9

Next day

-7.1+1.8-8.9+2.6-9.7

-4.0+2.5-6.5+2.7-6.7

-4.2-0.1-4.1+2.0-6.2

-2.5+1.4-3.9+2.1-4.6

-3.6+1.6-5.2+2.2-5.8

+1.7pendingpending+3.9-2.2

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

At the NCLT-convened meeting on October 24, 2026, 72 of 73 voting shareholders approved merging Hatri Pharma Private Limited into Venmax. The approval represented 72,10,542 of 72,10,692 valid votes, or 99.9979%. Public shareholders backed it with 6,283,767 votes for and 150 against. The merger still needs other approvals before it can take effect.

Likely market impact

Strong shareholder approval reduces merger approval risk, but the stock may remain sensitive to completion and post-merger business performance.